Kyntheum

Brodalumab, the active ingredient in Kyntheum, is a monoclonal antibody (IL‑17 receptor A antagonist) presented as a subcutaneous formulation for injection use. It is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who require systemic therapy.

GNH USA supplies Kyntheum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance, cold‑chain logistics and regulatory compliance for biologic medicines. Our network facilitates reliable access to biologic therapies across diverse markets.

Kyntheum is a biologic therapy that targets the IL‑17 pathway in inflammatory skin disease. - Plaque psoriasis: reduces erythema, scaling and plaque thickness, leading to improved skin appearance. - Moderate to severe disease: offers systemic control when topical therapies are insufficient. - Adult patients: provides an alternative for those who have not responded to other systemic agents.

Kyntheum may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Injection site reactions: redness, swelling or pain at the injection site. - Upper respiratory tract infection: symptoms such as sore throat or nasal congestion. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal discomfort.

Serious or Rare Side Effects: - Suicidal ideation or behavior: new or worsening thoughts of self‑harm. - Severe infections: including cellulitis, pneumonia or opportunistic infections. - Neutropenia: markedly reduced neutrophil counts increasing infection risk. - Allergic reactions: anaphylaxis or severe hypersensitivity. - Inflammatory bowel disease flare: new or worsening symptoms of Crohn's disease or ulcerative colitis.

Before initiating therapy, clinicians should assess patient history and monitor for specific safety concerns. - Infection screening: evaluate for active or latent infections, especially tuberculosis. - Mental health assessment: monitor for depression, suicidal thoughts or behavior throughout treatment. - Immunization status: administer necessary vaccines before starting therapy; avoid live vaccines during treatment. - Laboratory monitoring: periodic complete blood count and liver function tests are recommended. - Pregnancy and lactation: limited data; weigh potential benefits against unknown risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the product.

Brodalumab may interact with other agents that affect immune function or infection risk.

Major Interactions (Avoid): - Live vaccines: concurrent use can cause uncontrolled infection. - Systemic immunosuppressants (e.g., high‑dose corticosteroids): may markedly increase infection risk.

Moderate Interactions (Monitor Closely): - Other biologics targeting cytokines: overlapping immunomodulation may heighten adverse events. - Antifungal agents (e.g., azoles): may affect infection susceptibility. - Cytochrome P450 substrates: monitor for altered drug levels, although brodalumab itself is not a strong CYP modulator.